|
Jun 26
|
Veru And Two Other Penny Stocks To Consider
|
|
Jun 24
|
Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation
|
|
Jun 22
|
One Veru Insider Raised Stake By 150% In Previous Year
|
|
Jun 11
|
Veru to Participate in the Virtual BTIG Obesity Health Forum
|
|
Mar 12
|
Here's Why Veru (VERU) Looks Ripe for Bottom Fishing
|
|
Feb 20
|
3 US Penny Stocks With Market Caps Under $300M To Consider
|
|
Feb 14
|
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...
|
|
Feb 13
|
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
|
|
Dec 31
|
Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline
|
|
Dec 31
|
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business
|
|
Oct 9
|
Veru Inc (VERU) Q3 2024 Earnings Call Highlights: Strategic Cost Management and Revenue Growth ...
|
|
Aug 8
|
Veru Inc. (VERU) Reports Q3 Loss, Tops Revenue Estimates
|
|
Aug 8
|
Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results
|
|
Jul 29
|
Veru to Participate in the BTIG Virtual Biotechnology Conference
|
|
Jun 24
|
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions
|
|
Jun 18
|
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
|
|
Jun 17
|
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Shareholders
|
|
Jun 10
|
Veru to Present at the American Diabetes Association's 84th Scientific Sessions
|
|
May 15
|
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss
|
|
May 14
|
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week
|